Zhejiang University School of Medicine, Department of Cell Biology, Program in Molecular Cell Biology, Hangzhou, China.
Expert Opin Ther Targets. 2011 Aug;15(8):961-72. doi: 10.1517/14728222.2011.581232. Epub 2011 May 11.
Gastric cancer remains a major cancer burden in the world, with a poor 5-year survival rate. It is necessary to develop new effective therapeutic strategies to improve the long-term clinical outcome. MicroRNA (miRNA), a class of small non-coding RNA, has been identified as a key regulator of gene expression, and is implicated in the pathogenesis of gastric cancer.
This review summarizes the role of miRNAs in gastric carcinogenesis, with an emphasis on the expression and function of miR-375 in gastric cancer and beyond. It also discusses the opportunities and challenges of miR-375 as a potential therapeutic target for gastric cancer. The genes targeted by miR-375, including JAK2 and 3'-phosphoinositide dependent protein kinase-1 (PDK1), are also candidates for gastric cancer therapy.
Although radical surgery and rational chemotherapy are still the main treatment for gastric cancer, targeting miRNAs, in combination with other conventional therapies, may serve as a promising therapy strategy to improve the clinical outcome.
胃癌仍然是全球主要的癌症负担，其 5 年生存率较差。有必要开发新的有效治疗策略来改善长期临床结果。微 RNA（miRNA）是一类小的非编码 RNA，已被确定为基因表达的关键调节剂，与胃癌的发病机制有关。
本综述总结了 miRNA 在胃癌发生中的作用，重点介绍了 miR-375 在胃癌中的表达和功能及其在胃癌以外的作用。还讨论了 miR-375 作为胃癌潜在治疗靶点的机遇和挑战。miR-375 靶向的基因，包括 JAK2 和 3'-磷酸肌醇依赖性蛋白激酶-1（PDK1），也是胃癌治疗的候选基因。
尽管根治性手术和合理的化疗仍然是胃癌的主要治疗方法，但靶向 miRNA 结合其他常规疗法可能是一种有前途的治疗策略，可以改善临床结果。
